Tiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Read, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com

CIN : U85100MI 12005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D



UHID 12236109		Date	14/01/20	023		
UHID Name	Mr.Rahul Govind Kapure	Sex	Male	Age	31	
OPD Dental 12		Health Check Up				

Drug allergy: Sys illness:

Melaligned teek

Calculus # +

Delu oshodatic trestment

Adr OP 6.

De old prophylans.

Dilyhe Keke

Hiranandani Healthcare Pvt. Ltd. Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220

Emergency: 022 - B9199100 | Ambulance: 1255 For Appointment: D22 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





Altertida y Arter

JHID	12236109 Mr.Rahul Govind Kapure	Date Sex	14/01/20 Male	23 Age	31
Name OPD	Opthal 14		Check U		
				- 0	
	dur (douber), Dry us	Dru Svs	g allergy: • s illness: -	-> No	t know.
Ke	efunt (-power), Infin	<i>y</i>	s miness.	100	J
. No) [*]				-
;•					
1	- I A -	SPG 6	60 /	(1
	12-11/	> Ray 6		Bh	
) as 6	60	_	2
) RG - 2.0	0 - 0	NX	80 6 6.
	RI Z'		1		90. 6/6
		· la -2.0	0 - 10	3 40 X	
		24	MAL	ZR6 v	6
			NINE	٠, ١	$\mathcal{N}_{\mathbf{b}}$
	J.O.A.	DR 12-2.			
1	1.0.1.		1	ſ	. 01
				Λ	in Later Mill

Pfla- Feers



Hiranandani Fortis Hospital Mini Seashore Road, Sector 10 - A, Vashi, Navi Mumbai - 400 703. Tel.: +91-22-3919 9222

Fax: +91-22-3919 9220/21 Email: vashi@vashihospital.com

Signature

			12														ē.			U	ate:	17		1/
ame: <u>//^</u>	20	2M	ل یا	. 4	47.2	0		1<0	Di.														D.	
ame/[···					001	veo		- 4	TU	re	-	_Ag	e:	-	yrs			Sex:	M/	F				
10.10		195					m d	16	١							ì								
120/80	2 WI	ntiq	Heig	ght (d	cms)	:#	0	'	Cn	η W	eigh/	t(kg	s):	60	,	G	1	BMI	:					
Fig.			,	. 4	ž											ر ُ	,		e (£.					
e -88	ļ	olm					· ·				1				4									
WEIGHT Ibs	100	105	100	115	120	125	130	135	140	145	150	155	160	165.	170	175	190	185	100	105	200	205	240	
kgs										65.9	100000	10000	17.70	1 1 1										
EIGHT in/cm		1	lerwei				-					9	rweig		,		Obe		*				ly Ob	
0" - 152.4	19		21				1	,	27	28					00	0.4			- XII					
1" - 154.9			20			,-	1			27	29	30		32	33	34	35	36	37	38	39	40	41	
2" - 157.4	18		20		1					26		28	30	31	32	33	34	35	36	36	37	38	39	K
3" - 160.0	17	-							1	25		27	28	30	31	32	33	33	34	35	36	37	38	
4" - 162.5	17	18		1	-					24		26	27	28	29	31	32	32	33	34	35	36	37	
5" 165.1	16	17					1	1		24			26		28	29	30	31	32 ·	33	34	35	36	
6" - 167.6	16	17	4				21				24		25		27	28	29	29	31	32	33	34	35	
7" - 170.1	15	16	17	18				1		22					26		28	29	29	31	32	33	34	
3" - 172.7	15	16	16	17		_	-			22		1			25		27	28	28	29	30	31	33	
" - 176.2	14	15	16	17	_			-		21				اا			26	27	28	28	29	30	31	L
0" - 177.8	14	15	15	16	17	18	18	-	20			_	23				25		27	28	28	29	30	
1" - 180.3	14	14	15	16	16	17	18	18	19	20								25	26	27	28	28	29	
* - 182.8	13	14	14	15	16	17	17	18		19									25	26	27	27	28	
" - 185.4	13	13	14	15	15	16	17	17	18		_	-					15.1.00	24			26	27	27	
" - 187.9	12	13	14	14	15	16	16	17	18							_		23			25	26	27	
3" - 190.5	12	13	13	14	15	15	16	16	17	18			-		-			23	-				26	2
" - 193.0	12	12	13	14	14	15	15	16	17	17	18							22						2
																			_	(*)			للسا	
v	-										-			4			- 4						,	
octors Not	es:							14						2								44		
e ^ =																								
													-			5				- 6				_
= 3																								
				; 4																		-		
					2																			
																					101.3		14	
								-		_	-	-							/w					_
	i.e.												12.7		2				100					Ť
			_								-										:		_	_
		197		-																				
5																								_
all									ef.						ű.		2)							
S SI	77								ř						űi		Đ.			Q.				





Final

PATIENT ID: FH.12236109 CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002870 AGE:

31 Years

SEX: Male

REFERRING DOCTOR:

ABHA NO:

REPORTED:

14/01/2023 14:37:37

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

DRAWN: 14/01/2023 12:49:00

RECEIVED: 14/01/2023 12:50:33

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375 CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Results

Biological Reference Interval

Units

BIOCHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

94

70 - 139

mg/dL

METHOD: HEXOKINASE

Test Report Status

Comments

NOTE: POST PRANDIAL PLASMA GLUCOSE VALUES. TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr.Akta Dubey

Counsultant Pathologist

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report









PATIENT NAME: MR.RAHUL GOVIND KAPURE

PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO:

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

14/01/2023 16:44:39

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

154.3

80 - 200

ng/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

8.15

5.1 - 14.1

µg/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

2,700

0.270 - 4.200

μIU/mL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

Interpretation(s)

TSH (ULTRASENSITIVE)

BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR


4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,

Scan to View Details



Scan to View Report

Page 1 Of 2



Patient Ref. No. 22000000822379







PATIENT NAME: MR.RAHUL GOVIND KAPURE

PATTENT ID :

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO :

14/01/2023 16:44:39

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SFIF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN

1.160

< 1.4

ng/mL

METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

Interpretation(s)
PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis. PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patient.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

- Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA (false positive) levels persisting up to 3 weeks.

As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines-

Age of male Reference range (ng/ml)

40-49 years 0-2.5 50-59 years 0-3.5 60-69 years 0-4.5

70-79 years 0-6.5

(* conventional reference level (< 4 ng/ml) is already mentioned in report, which covers all agegroup with 95% prediction interval)

References- Teitz ,textbook of clinical chemiistry, 4th edition) 2.Wallach's Interpretation of Diagnostic Tests

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam

Birmhadham

Consultant Pathologist

BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR

4. KHARGHAR

Tel: 9111591115,

NAVI MUMBAI, 410210 MAHARASHTRA, INDIA

Scan to View Details



Scan to View Report

Page 2 Of 2 Patient Ref. No. 22000000822379



LABORATEON NAMEO MR. RAHUL GOVIND KAPURE

CLIENT PATIENT ID : UID:12236109

PATIENT ID:

FH.12236109

ACCESSION NO: 0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO: REPORTED:

14/01/2023 15:45:11

DRAWN: 14/01/2023 09:15:00 CLIENT NAME : FORTIS VASHI-CHC -SPLZD

RECEIVED: 14/01/2023 09:14:52

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731


BILLNO-1501230PCR002731	Results	Biological Reference Interval Units
Test Report Status <u>Final</u>	Keaulta	Proposition Section 2015 to the Conference of the Conference of the Conference of
KIDNEY PANEL - 1		
BLOOD UREA NITROGEN (BUN), SERUM		
	7	6 - 20 mg/dL
BLOOD UREA NITROGEN METHOD: UREASE - UV		
CREATININE EGFR- EPI		
	0.66	Low 0.90 - 1.30 mg/dL
CREATININE METHOD: ALKALINE PICRATE KINETIC JAFFES		
AGE	31	years
GLOMERULAR FILTRATION RATE (MALE)	128.60	Refer Interpretation Below mL/min/1.73
METHOD : CALCULATED PARAMETER		
BUN/CREAT RATIO		
BUN/CREAT RATIO	10.61	5.00 - 15.00
METHOD : CALCULATED PARAMETER		
URIC ACID, SERUM		
URIC ACID	5.3	3.5 - 7.2 mg/dL
METHOD: URICASE UV		
TOTAL PROTEIN, SERUM		*
TOTAL PROTEIN	7.6	6.4 - 8.2 g/dL
METHOD: BIURET		
ALBUMIN, SERUM		
ALBUMIN	4,2	3.4 - 5.0 g/dL
METHOD : BCP DYE BINDING		
GLOBULIN		
GLOBULIN	3.4	2.0 - 4.1 g/dL
METHOD: CALCULATED PARAMETER		
ELECTROLYTES (NA/K/CL), SERUM		
SODIUM, SERUM	136	136 - 145 mmol/L
METHOD : ISE INDIRECT		
POTASSIUM, SERUM	4.92	3.50 - 5.10 mmol/L
METHOD: ISE INDIRECT		one comment to
CHLORIDE, SERUM	102	98 - 107 mmol/L
METHOD : ISE INDIRECT		

PHYSICAL EXAMINATION, URINE

Interpretation(s)

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,







Scan to View Report





NAME : MR.RAHUL GOVIND KAPURE





Units

PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO: 0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO:

14/01/2023 15:45:11

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

DILLING THE	1.04011 5		전 전 보 보 수가입니다.
	5000AV	Results	Biological Reference Interval
Test Report Status	<u>Final</u>	Kesuits	

COLOR

PALE YELLOW

METHOD: PHYSICAL

APPEARANCE

CLEAR

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

7 0

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD 1.010 SPECIFIC GRAVITY METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

1.003 - 1.035

PROTFIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

GLUCOSE METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

NOT DETECTED

NOT DETECTED

KETONES

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

NOT DETECTED

BII IRUBIN METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

NOT DETECTED

NORMAL

NORMAL UROBILINOGEN METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NITRITE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S)

EPITHELIAL CELLS

0 - 1

0-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

1-2

0-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

CASTS

NOT DETECTED

CRYSTALS

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,







Scan to View Details Scan to View Report







PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002783 AGE:

31 Years

SEX: Male

ABHA NO:

14/01/2023 15:45:11

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Test Report	Status	<u>Final</u>

Results

Biological Reference Interval

BACTERIA

NOT DETECTED

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED.

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

REMARKS

URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT.

Interpretation(s)

Interpretation(s)
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Fallure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.
CREATININE EGFR- EPI-GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test.
CREATININE EGFR- EPI-GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR pelow 60 may mean kidney disease.

A GFR of 60 or higher is in the normal range.

A GFR below 60 may mean kidney disease.

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney function than serum creatinine alone.

Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

Disease (MDRD) Study equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, of CKD.

The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Bedside GFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

But a contract the model of the model that the model of the model that the model of the model that the model of t

Synurome

Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein,also known as total protein, is a biochemical test for measuring the total amount of protein in serum. made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom 's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

syndrome, Protein-losing enteropatny etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10. NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report





LABORATORY REPORT PATIENT NAME : MR.RAHUL GOVIND KAPURE





PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO :

14/01/2023 15:45:11

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Test Report Status Final

Results

Biological Reference Interval

HAEMATOLOGY - CBC

CBC-5, EDTA WHOLE BLOOD

MORPHOLOGY

RRC

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

METHOD: MICROSCOPIC EXAMINATION

WBC

NORMAL MORPHOLOGY

METHOD: MICROSCOPIC EXAMINATION

PLATELETS

ADEQUATE

METHOD: MICROSCOPIC EXAMINATION

BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB) METHOD: SPECTROPHOTOMETRY RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE WHITE BLOOD CELL (WBC) COUNT METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CYTOMETRY

6.00

267

47.9

90.3

29.8

33.0

15.5

15.8

5.30

4.0 - 10.0

13.0 - 17.0

4.5 - 5.5

150 - 410

40 - 50

83 - 101

27.0 - 32.0

31.5 - 34.5

thou/µL

thou/µL

%

pg

g/dL

%

mil/µL

g/dL

PLATELET COUNT METHOD: ELECTRICAL IMPEDANCE

RBC AND PLATELET INDICES

HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER

MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER

MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER

MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD: CALCULATED PARAMETER

RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER

MENTZER INDEX MEAN PLATELET VOLUME (MPV)

METHOD: CALCULATED PARAMETER

NEUTROPHILS

17.0

8.2

6.8 - 10.9

High 11.6 - 14.0

fL

WBC DIFFERENTIAL COUNT

47

40 - 80

%

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA


Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report





LABORATORY REPORT PATIENT NAME: MR.RAHUL GOVIND KAPURE





PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002783 AGE:

31 Years

SEX: Male

ABHA NO:

REPORTED:

14/01/2023 15:45:11

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

BILLNO-1501230PCR002/31	Daoulto	Biological Reference	Interval
Test Report Status <u>Final</u>	Results	Diologica, i.e.	
METHOD: FLOWCYTOMETRY	37	20 - 40	%
LYMPHOCYTES	37	Det 10 s	
METHOD: FLOWCYTOMETRY	10	2 - 10	%
MONOCYTES	10	-	
METHOD: FLOWCYTOMETRY	06	1 - 6	%
EOSINOPHILS	06		
METHOD: FLOWCYTOMETRY	00	0 - 2	%
BASOPHILS	00		
METHOD : FLOWCYTOMETRY	2.82	2.0 - 7.0	thou/µL
ABSOLUTE NEUTROPHIL COUNT	2.02		
METHOD : CALCULATED PARAMETER	2.22	1.0 - 3.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.22		
METHOD : CALCULATED PARAMETER	0.6	0.2 - 1.0	thou/µL
ABSOLUTE MONOCYTE COUNT	0.0		
METHOD : CALCULATED PARAMETER	0.36	0.02 - 0.50	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.50		
METHOD : CALCULATED PARAMETER	0	Low 0.02 - 0.10	thou/µL
ABSOLUTE BASOPHIL COUNT	•		
METHOD : CALCULATED PARAMETER	1.3		
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1,5		
METHOD: CALCULATED PARAMETER			

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was a prognostic positive was a prognost

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R

02

0 - 14

mm at 1 hr

METHOD: WESTERGREN METHOD

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report





LABORATORY NAME PAR. RAHUL GOVIND KAPURE



PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO: 0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO:

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

14/01/2023 15:45:11

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Test Report Status

Final

Results

Biological Reference Interval

Interpretation(s)

ENTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR. ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with the physician to search for a v

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickieCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE AB

METHOD: TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods

BIOCHEMISTRY

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL

0.65

0.2 - 1.0

mg/dL

METHOD: JENDRASSIK AND GROFF

0.18

0.0 - 0.2

mg/dL

BILIRUBIN, DIRECT METHOD: JENDRASSIK AND GROFF

BILIRUBIN, INDIRECT

0.47

0.1 - 1.0

mg/dL Page 6 Of 10

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10.

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report



Patient Ref. No. 22000000822379







PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO: 0022WA002783 AGE: 31 Years

SEX: Male RECEIVED: 14/01/2023 09:14:52 ABHA NO:

REPORTED:

14/01/2023 15:45:11

DRAWN: 14/01/2023 09:15:00 CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

BILLNO-1501230PCR0	02731		Biological Reference	e Interval
Test Report Status	<u>Final</u>	Results	Biological Reference	
METHOD : CALCULATED PARTOTAL PROTEIN	RAMETER	7.6	6.4 - 8.2	g/dL
METHOD : BIURET ALBUMIN		4.2	3.4 - 5.0	g/dL
METHOD: BCP DYE BINDIN GLOBULIN	IG	3.4	2.0 - 4.1	g/dL
METHOD : CALCULATED PA		1.2	1.0 - 2.1	RATIO
METHOD : CALCULATED PA	RAMETER ANSFERASE (AST/SGOT)	22	15 - 37	U/L
	ISFERASE (ALT/SGPT)	33	< 45.0	U/L
METHOD: UV WITH P5P ALKALINE PHOSPHAT	ASE	123	High 30 - 120	U/L
METHOD : PNPP-ANP GAMMA GLUTAMYL T	RANSFERASE (GGT)	31	15 - 85	U/L
METHOD: GAMMA GLUTA LACTATE DEHYDROG METHOD: LACTATE -PYRI		137	100 - 190	U/L
GLUCOSE FASTING FBS (FASTING BLOC METHOD : HEXOKINASE	i,FLUORIDE PLASMA DD SUGAR)	95	74 - 99	mg/dL
GLYCOSYLATED H WHOLE BLOOD HBA1C	EMOGLOBIN(HBA1C), E	DTA 5.4	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - Diabetics: > or = 6 Therapeutic goals: Action suggested: (ADA Guideline 202	6.4 5.5 < 7.0 > 8.0
METHOD: HB VARIANT ESTIMATED AVERA METHOD: CALCULATED	GE GLUCOSE(EAG)	108.3	< 116.0	mg/dL

Interpretation(s)
LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,







Scan to View Report





PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002783 AGE:

SEX: Male

ABHA NO:

14/01/2023 15:45:11

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

31 Years

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Results

Biological Reference Interval

Test Report Status

Final

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or permicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the hody. AST is found in the liver, heart, shelptal guide, being and and the liver heart, shelptal guide.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic clinically as a marker for liver health. AST levels increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all hody fissues Tissues with blobar amounts of ALD include the liver in the liver.

nepatoteijular injury, to determine liver nealin. AST levels increase during acute nepatos, sometimes due to a viral infection, schemal to the liver, circuite hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, and the liver, bile during the liver, bile ducts, and bone. Elevated ALP levels are seen in Biliary obstruction, and protein deficiency, wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is a highest concentration is in the kidney, but the liver is considered the source of is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of is also found in other tissues mainly in the liver. Series of the liver, blanch and used of the liver, brain and seminal vesicles. The highest concentration in the kidney, but the liver and the series of the liver and used of the liver, and the liver and used to a series of the liver, and the protein in the plasma and use of enzyme-inducing drugs etc. Series that increase vessel in the liver and used the liver and used to a series of the liver, and used to a series of the liver, and used to a series of the liver, and used to the liver and used to the liver and used to the liver and use

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

pecreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:
While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.
High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic lindex & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.
3.Identifying patients at increased risk for diabetes (prediabetes).
3.Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to:

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Vitamin C & E are reported to falsely lower test results. Hypertriphyseridemia uremia, byserbility/hipemia, chronic alcoholism chronic indestion of salicylates & on

II.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,







Scan to View Report

Page 8 Of 10 Patient Ref. No. 2200000082237



LABORATORY REPORT PATIENT NAME: MR.RAHUL GOVIND KAPURE





PATIENT ID:

FH.12236109

CLIENT PATIENT ID: UID:12236109

ACCESSION NO:

0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO:

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

14/01/2023 15:45:11

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Test Report Status

Final

Results

Biological Reference Interval

BIOCHEMISTRY - LIPID

TOTO DECETIF SERU	M	

CHOLESTEROL, TOTAL

129

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES

85

< 150 Normal

mg/dL

150 - 199 Borderline High 200 - 499 High

>/=500 Very High

METHOD: ENZYMATIC ASSAY

HDL CHOLESTEROL

44

< 40 Low

mg/dL

>/=60 High

METHOD: DIRECT MEASURE - PEG

LDL CHOLESTEROL, DIRECT

76

< 100 Optimal

mg/dL

100 - 129 Near or above optimal 130 - 159 Borderline High

160 - 189 High

>/= 190 Very High

METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

NON HDL CHOLESTEROL

85

Desirable: Less than 130

Above Desirable: 130 - 159

Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

METHOD: CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN

17.0

</= 30.0

mg/dL

mg/dL

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO

2.9

Low 3.3 - 4.4 Low Risk

4.5 - 7.0 Average Risk

7.1 - 11.0 Moderate Risk

> 11.0 High Risk

METHOD: CALCULATED PARAMETER

LDL/HDL RATIO

1.7

0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER

Interpretation(s)

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10. NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report





LABORATORY REPORT
PATIENT NAME: MR.RAHUL GOVIND KAPURE

CLIENT PATIENT ID: UID:12236109

PATIENT ID: ACCESSION NO:

FH.12236109

0022WA002783 AGE: 31 Years

SEX: Male

ABHA NO :

14/01/2023 15:45:11

DRAWN: 14/01/2023 09:15:00

RECEIVED: 14/01/2023 09:14:52

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

Final

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

Test Report Status

UID:12236109 REQNO-1358375

CORP-OPD

BILLNO-1501230PCR002731 BILLNO-1501230PCR002731

Results

Biological Reference Interval

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr. Akta Dubey

Counsultant Pathologist

Dr. Rekha Nair, MD

Microbiologist

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,




Scan to View Details



Scan to View Report

Page 10 Of 10

Patient Ref. No. 22000000822



Hiranandani Healthcare Pvt. Ltd. Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D

(For Billing/Reports & Discharge Summary only)





Date: 14/Jan/2023

DEPARTMENT OF NIC

UHID | Episode No: 12236109 | 2806/23/1501

Order No | Order Date: 1501/PN/OP/2301/5719 | 14-Jan-2023

Admitted On | Reporting Date: 14-Jan-2023 13:19:39

Order Doctor Name: Dr.SELF.

Name: Mr. Rahul Govind Kapure Age | Sex: 31 YEAR(S) | Male Order Station: FO-OPD

Bed Name:

ECHOCARDIOGRAPHY TRANSTHORACIC

FINDINGS:

- No left ventricle regional wall motion abnormality at rest.
- Normal left ventricle systolic function. LVEF = 60%.
- No left ventricle diastolic dysfunction.
- No left ventricle Hypertrophy. No left ventricle dilatation.
- · Structurally normal valves.
- No mitral regurgitation.
- No aortic regurgitation. No aortic stenosis.
- No tricuspid regurgitation. No pulmonary hypertension.
- Intact IAS and IVS.
- No left ventricle clot/vegetation/pericardial effusion.
- Normal right atrium and right ventricle dimensions.
- Normal left atrium and left ventricle dimension.
- Normal right ventricle systolic function, No hepatic congestion.

M-MODE MEASUREMENTS:

1-MODE MEASUREMES		
THE STATE OF THE S	33	mm
LA	25	mm
AO Root	17	mm
AO CUSP SEP	23	mm
LVID (s)	37	mm
LVID (d)	09	mm
IVS (d)	10	mm
LVPW (d)	29	mm
RVID (d)	28	mm
RA	60	%
LVEF		

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U8: 00MH2005PTC 154823

GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D

(For Billing/Reports & Discharge Summary only)





DEPARTMENT OF NIC

Date: 14/Jan/2023

Name: Mr. Rahul Govind Kapure

Age | Sex: 31 YEAR(S) | Male Order Station: FO-OPD

Bed Name:

UHID | Episode No: 12236109 | 2806/23/1501

Order No | Order Date: 1501/PN/OP/2301/5719 | 14-Jan-2023 Admitted On | Reporting Date: 14-Jan-2023 13:19:39

Order Doctor Name : Dr.SELF .

DOPPLER STUDY:

E WAVE VELOCITY: 0.8 m/sec. A WAVE VELOCITY:0.5 m/sec

E/A RATIO:1.5

	PEAK (mmHg)	MEAN (mmHg)	V max (m/sec)	GRADE OF REGURGITATION
	(mmrig)	(1111- 8)		Nil
MITRAL VALVE	IN OF			Nil
AORTIC VALVE	0.5		-	Nil
TRICUSPID VALVE	N_			Nil
PULMONARY VALVE	2.0		1	L

Final Impression:

Normal 2 Dimensional and colour doppler echocardiography study.

DR. PRASHANT PAWAR

DNB(MED), DNB (CARDIOLOGY)

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 14/Jan/2023

Name; Mr. Rahul Govind Kapure

Age | Sex: 31 YEAR(S) | Male

Order Station: FO-OPD

Bed Name:

UHID | Episode No : 12236109 | 2806/23/1501 Order No | Order Date: 1501/PN/OP/2301/5719 | 14-Jan-2023

Admitted On | Reporting Date: 14-Jan-2023 16:13:17

Order Doctor Name : Dr.SELF .

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax are unremarkable.

DR. VIVEK MANE

MBBS., DMRE. (Radiologist)

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 14/Jan/2023

Name: Mr. Rahul Govind Kapure

Age | Sex: 31 YEAR(S) | Male

Order Station : FO-OPD

Bed Name:

UHID | Episode No : 12236109 | 2806/23/1501

Order No | Order Date: 1501/PN/OP/2301/5719 | 14-Jan-2023

Admitted On | Reporting Date: 14-Jan-2023 12:19:02

Order Doctor Name : Dr.SELF.

US-WHOLE ABDOMEN

LIVER is normal in size and echogenicity. Intrahepatic portal and biliary systems are normal. No focal lesion is seen in liver. Portal vein appears normal.

GALL BLADDER is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection. CBD appears normal in caliber.

SPLEEN is normal in size and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 9.8 x 4.4 cm.

Left kidney measures 9.1 x 4.8 cm.

PANCREAS is normal in size and morphology. No evidence of peripancreatic collection.

URINARY BLADDER is partially distended. Bladder wall is normal in thickness. No evidence of intravesical mass/calculi.

PROSTATE is normal in size & echogenicity. It measures ~ 20.3 cc in volume.

No evidence of ascites.

IMPRESSION:

No significant abnormality is detected.

DR. CHETAN KHADKE

M.D. (Radiologist)